Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Inc. said more than 20,000 prescriptions have been dispensed for its new non-addictive painkiller, a sign that the drug is gaining some early traction as it attempts to ...

Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall.

Excluding items, Vertex Pharmaceuticals Inc. reported adjusted earnings of $1.054 billion or $4.06 per share for the period. Analysts on average had expected the company to earn $4.29 per share.

Vertex Pharmaceuticals Inc. said it's stopping work on two potential drugs for a genetic lung disorder, but is now predicting a better-than-expected 2024 product revenue.

News about Vertex Pharmaceuticals Inc., including commentary and archival articles published in The New York Times.

Excluding items, Vertex Pharmaceuticals Inc. reported adjusted earnings of $1.10 billion or $4.20 per share for the period. Analysts on average had expected the company to earn $4.10 per share, ...

Jefferies has upgraded Vertex Pharmaceuticals Inc. VRTX, citing the company’s robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion ...

Vertex Pharmaceuticals Inc. ( (VRTX)) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc. presented to its investors. Vertex Pharmaceuticals Inc., a ...

Block & Leviton is investigating Vertex Pharmaceuticals Inc. (Nasdaq:VRTX) for potential securities law violations. Investors who have lost money ...

Vertex Pharmaceuticals Inc. took a step toward a new form of non-opioid pain treatment, advancing development of an experimental therapy that met its main goal in two studies.